The primary goal of the highly active antiretroviral treatment is to improve HIV-infected patient immune function through maintaining viral suppression. However, this treatment may lead to adverse events, some of them potentially serious. This article emphasizes on the antiretroviral therapy associated adverse events and their management recommendations, especially for serious or potentially life-threatening cases. Adverse events analyzed in this article include side effects derived from mitochondrial toxicity, abacavir hypersensitivity reaction, hepatotoxicity, skin rash and Stevens-Johnson syndrome, increased bleeding episodes in hemophilic patients and nephrotoxicity. In some cases, a high suspicion is needed because the onset symptoms may be unspecific.

Download full-text PDF

Source
http://dx.doi.org/10.1157/13088948DOI Listing

Publication Analysis

Top Keywords

adverse events
12
[antiretroviral treatment
4
treatment associated
4
associated life-threatening
4
adverse
4
life-threatening adverse
4
adverse events]
4
events] primary
4
primary goal
4
goal highly
4

Similar Publications

Introduction: Mobilization protocols are safe and feasible for critically ill pediatric patients in the intensive care unit (ICU), but barriers exist to sustainability. This study described a focused early mobility protocol, sustained over 5 years, which is on time for therapy consults and patient mobilization at a single institution.

Methods: A formal ICU mobility protocol was implemented as part of a unit-wide ICU liberation bundle.

View Article and Find Full Text PDF

The aim of the present study was to investigate the efficacy and safety of anlotinib combined with vinorelbine (NVB) as a second-line treatment for elderly patients with advanced squamous cell lung carcinoma (SqCLC). The present retrospective analysis included 48 elderly patients (aged ≥65 years) diagnosed with advanced SqCLC who received anlotinib in combination with NVB as a second-line therapy between January 2021 and December 2023. The primary endpoints assessed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety profile.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the "obesity paradox," focusing on overweight and obese patients who underwent percutaneous coronary intervention (PCI) for coronary artery disease.
  • Over a follow-up period averaging about 65 months, results showed that 17.4% of patients experienced adverse cardiovascular events, with a notable J-shaped relationship indicating that those classified as overweight (BMI 25.0-29.9 kg/m) had lower risks of total and major cardiovascular events.
  • The findings suggest that overweight individuals may have better cardiovascular outcomes post-PCI compared to those with a normal BMI.
View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) increases the risks of stroke and mortality. It remains unclear whether rhythm control reduces the risk of stroke in patients with AF concomitant with hypertrophic cardiomyopathy (HCM).

Methods: We identified AF patients with HCM who were ≥ 18 years old in the Taiwan National Health Insurance Database.

View Article and Find Full Text PDF

Aims: This study aims to verify the feasibility and safety of percutaneous coronary intervention (PCI) after a distal transradial approach (dTRA) with radial artery occlusion (RAO) recanalization.

Methods: Between July 2018 and January 2022, 30 patients underwent PCI following attempted RAO recanalization via dTRA. Among these cases, the target radial arteries could not be recanalized in five patients, necessitating alternative vascular access.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!